- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Westbrook Today
By the People, for the People
Wall Street Zen Downgrades IDEXX Laboratories (NASDAQ:IDXX) to Buy
Analysts lower rating from "strong-buy" to "buy" for the veterinary diagnostic company
Published on Feb. 28, 2026
Got story updates? Submit your updates here. ›
Wall Street Zen, an equity research firm, has downgraded shares of IDEXX Laboratories (NASDAQ:IDXX) from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday. IDEXX Laboratories is a global developer, manufacturer, and provider of diagnostic products and services primarily for the animal health, water testing, and food safety markets.
Why it matters
This downgrade from Wall Street Zen comes as IDEXX Laboratories has seen its stock price fluctuate in recent months, with the company's shares trading between a 52-week low of $356.14 and a 52-week high of $769.98. The change in rating could impact investor sentiment and the stock's performance going forward.
The details
In the research note, Wall Street Zen cited several factors that led to the downgrade, including a recent report from Leerink Partners that set a price target of $785 for IDEXX shares, as well as a cut to the company's rating by Weiss Ratings from "buy (b-)" to "hold (c+)". Additionally, JPMorgan Chase & Co. boosted its price target for IDEXX from $675 to $775, while Barclays dropped its price objective from $850 to $800.
- The downgrade was issued on Saturday, February 28, 2026.
The players
Wall Street Zen
An equity research firm that provides analysis and ratings on publicly traded companies.
IDEXX Laboratories
A global developer, manufacturer, and provider of diagnostic products and services primarily for the animal health, water testing, and food safety markets.
Leerink Partners
An investment bank and research firm that covers the healthcare sector.
Weiss Ratings
A financial research and ratings agency that provides independent analysis of stocks, mutual funds, and other financial products.
JPMorgan Chase & Co.
A multinational investment bank and financial services company.
Barclays
A British multinational investment bank and financial services company.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
This downgrade from Wall Street Zen highlights the ongoing volatility in IDEXX Laboratories' stock price and the mixed views from analysts on the company's future performance. Investors will be closely watching to see how the stock reacts to this latest rating change and whether IDEXX can maintain its position as a leader in the veterinary diagnostics market.
